Important Information for Regeneron Pharmaceuticals Investors: Rosen Law Firm Reminds of Class Action Lawsuit and Lead Plaintiff Deadline
On March 10, 2025, Rosen Law Firm, a global investor rights law firm, issued a press release reminding purchasers of securities of Regeneron Pharmaceuticals, Inc. (Regeneron) between November 2, 2023, and October 30, 2024 (the “Class Period”), of the important lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Regeneron and certain of its executives made false and misleading statements and/or failed to disclose material information during the Class Period.
Background on the Class Action Lawsuit
According to the complaint, defendants made false and/or misleading statements and/or failed to disclose that:
- Regeneron’s Eylea product faced increasing competition from biosimilars;
- Regeneron’s sales growth was decelerating;
- Regeneron’s research and development pipeline was not progressing as planned;
- Regeneron was experiencing manufacturing issues with its Eylea and Dupixent products;
- Regeneron’s financial results would be negatively impacted.
As a result of these allegedly false and misleading statements, Regeneron’s stock traded at artificially inflated prices during the Class Period, causing investors harm.
Impact on Individual Investors
If you purchased Regeneron securities during the Class Period and suffered a loss, you may be eligible to act as a lead plaintiff in the class action. As a lead plaintiff, you may have the ability to help direct the litigation and participate in important decision-making.
Impact on the World
The outcome of this class action lawsuit could have significant implications for the biopharmaceutical industry as a whole. It could set a precedent for how similar cases are handled in the future, potentially leading to increased transparency and accountability from publicly traded companies. Additionally, the lawsuit could result in Regeneron paying damages to affected investors, potentially impacting the company’s financial stability.
Conclusion
If you purchased Regeneron securities during the Class Period and believe you may have been harmed as a result of the allegedly false and misleading statements, you may be eligible to act as a lead plaintiff in the class action lawsuit. It is important to take action before the lead plaintiff deadline on March 10, 2025. For more information, contact Rosen Law Firm.
This information is provided for informational purposes only and should not be considered legal advice. If you have any questions about this topic or any other legal matter, you should consult with an attorney.
